[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"weight-reduction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:weight-reduction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100632398","phase-4-low-dose-semaglutide-for-weight-loss-in-obese-non-diabetic-pakistani-adults-100632398",false,"NCT07513168","Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults","Efficacy and Safety of Low-Dose Semaglutide for Weight Loss and Cardiometabolic Improvement in Obese Pakistani Adults Without Type 2 Diabetes: A Single-Arm Open-Label Single-Center Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Body mass index (BMI ≥ 27.5 kg\u002Fm²) according to WHO Asian cut-offs.\n* No diagnosis of type 2 diabetes mellitus, confirmed by:\n\nFasting blood glucose \\\u003C 126 mg\u002FdL, and HbA1c \\\u003C 6.5% within three months prior to enrollment.\n\n* Willingness and ability to provide written informed consent.\n* Willingness to comply with study procedures, including weekly injections and lifestyle counseling.\n\nExclusion Criteria:\n\n* History of pancreatitis.\n* History or presence of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).\n* Pregnant or lactating women.\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or hepatic impairment (ALT or AST \\> 3× upper limit of normal).\n* Current use of other anti-obesity medications.\n* Known hypersensitivity to semaglutide or any component of the formulation.\n* Any condition that, in the investigator's opinion, would interfere with participation, adherence, or safety in the study.","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without type 2 diabetes mellitus. The study will be conducted at the Asian Institute of Medical Sciences (AIMS), Hyderabad, Sindh, Pakistan. A total of 60 obese adults aged 18 years or older with a body mass index (BMI) of 27.5 kg\u002Fm² or greater according to World Health Organization Asian cutoffs and without type 2 diabetes mellitus (fasting blood glucose \\\u003C126 mg\u002FdL and HbA1c \\\u003C6.5%) will be enrolled. Eligible participants will receive once-weekly subcutaneous semaglutide following a standard dose titration schedule of 0.25 mg weekly for four weeks, 0.5 mg weekly for four weeks, and 1.0 mg weekly for the remaining 16 weeks, for a total treatment duration of 24 weeks. All participants will receive standardized lifestyle counseling, including a hypocaloric diet with a 500-750 kcal\u002Fday deficit and at least 150 minutes per week of moderate-intensity physical activity. The primary outcome is the percentage change in body weight from baseline to 24 weeks. Secondary outcomes include changes in body mass index, waist circumference, systolic and diastolic blood pressure, lipid profile (total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides), liver enzymes (alanine aminotransferase and aspartate aminotransferase), and quality of life. Safety will be assessed through continuous monitoring of adverse events and adverse drug reactions with causality assessment using the Naranjo Adverse Drug Reaction Probability Scale. Clinical and laboratory assessments will be conducted at baseline, 12 weeks, and 24 weeks. Data will be analyzed using descriptive and inferential statistics, including paired t-tests or non-parametric equivalents and repeated measures analysis, with a significance level of p \\\u003C 0.05. The study will be conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki, with approval from the AIMS Institutional Review Board and written informed consent obtained from all participants. The trial aims to generate locally relevant clinical evidence on the effectiveness and safety of low-dose semaglutide for obesity management in non-diabetic Pakistani adults.",[26,27,28],"Obesity","Weight Reduction","Cardiometabolic Risk Factors",[30,26,31,32,33,34,35,36,37,38],"Semaglutide","Weight loss","GLP-1 Receptor Agonist","Body Mass Index","Open label trial","Cardiometabolic risk","Single Arm Study","Pakistan","Obesity Pharmacotherapy","RECRUITING","2026-04-01",{"date":42,"type":43},"2026-04-06","ACTUAL",{"date":45,"type":43},"2025-08-01",{"date":47,"type":20},"2026-12-01",{"name":49,"class":50},"Asian Institute Of Medical Sciences","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":17,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100558656","athlete-biochemical-monitoring-and-nutritional-support-100558656","NCT06553963","Athlete Biochemical Monitoring and Nutritional Support","Biochemical Monitoring and Nutritional Support During Pre-Competition Weight Reduction in Female Weightlifters: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 30 years old\n* At least 5 years of professional weightlifting training experience\n* Currently undergoing systematic training\n* Passed a health examination\n* The study complies with the Declaration of Helsinki and signed an informed consent form.\n\nExclusion Criteria:\n\n* Obvious injuries to the lower limb joints\n* Taking prescription medications (such as those affecting mood and sleep)\n* Abnormal cardiovascular function.",true,"FEMALE","30 Years",{"count":63,"type":20},28,[65],"NA","The objective of this study is to evaluate the efficacy of physiological and biochemical monitoring along with nutritional support in improving the performance and well-being of female weightlifters during the critical weight reduction phase before competition. It also seeks to determine the safety and potential benefits of the personalized nutritional interventions.\n\nThe primary questions this study aims to address are:\n\nDoes personalized nutritional support, informed by physiological and biochemical monitoring, reduce the incidence of fatigue and improve sleep quality in female weightlifters during the pre-competition period? How do serum indicators change in response to the nutritional interventions, and what does this indicate about the athletes' health and performance? What are the perceived benefits and any potential adverse effects reported by the participants receiving the nutritional support? To assess the impact of the intervention, researchers will compare the outcomes of the experimental group, which receives the tailored nutritional support, to those of the control group, which follows standard practices without additional intervention.\n\nParticipants will be required to:\n\nConsume the nutritional supplements or maintain their regular diet as assigned for the duration of the 1-month study.\n\nAttend scheduled visits to the research facility every two weeks for comprehensive health assessments, including blood tests for serum indicators and evaluations of fatigue levels and PSQI scores.\n\nRecord their daily experiences, including dietary adherence, training intensity, perceived fatigue, sleep patterns, and any other relevant observations in a personal diary.\n\nBy conducting this randomized controlled trial, the study will provide valuable insights into the role of targeted nutritional support in enhancing athletic performance and overall health during the demanding pre-competition weight reduction period.",[27],"NOT_YET_RECRUITING","2024-08-14",{"date":71,"type":43},"2024-08-16",{"date":73,"type":20},"2024-08-20",{"date":75,"type":20},"2024-09-20",{"name":77,"class":50},"Chengdu Sport University"]